Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 1210 citing articles:

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer A. Wargo, et al.
Cell (2017) Vol. 168, Iss. 4, pp. 707-723
Open Access | Times Cited: 4390
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, et al.
New England Journal of Medicine (2014) Vol. 372, Iss. 4, pp. 311-319
Open Access | Times Cited: 3360
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian, Janis M. Taube, Robert A. Anders, et al.
Nature reviews. Cancer (2016) Vol. 16, Iss. 5, pp. 275-287
Open Access | Times Cited: 2396
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, et al.
Leukemia (2022) Vol. 36, Iss. 7, pp. 1720-1748
Open Access | Times Cited: 2321
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor, Andrew J. Rech, Amit Maity, et al.
Nature (2015) Vol. 520, Iss. 7547, pp. 373-377
Open Access | Times Cited: 2206
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2040
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elı́as Campo, Steven H. Swerdlow, Nancy L. Harris, et al.
Blood (2011) Vol. 117, Iss. 19, pp. 5019-5032
Open Access | Times Cited: 1913
Regulation and Function of the PD-L1 Checkpoint
Chong Sun, Riccardo Mezzadra, Ton N. Schumacher
Immunity (2018) Vol. 48, Iss. 3, pp. 434-452
Open Access | Times Cited: 1825
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy, Chip Stewart, Andrew Dunford, et al.
Nature Medicine (2018) Vol. 24, Iss. 5, pp. 679-690
Open Access | Times Cited: 1571
Combining immunotherapy and targeted therapies in cancer treatment
Matthew W. Vanneman, Glenn Dranoff
Nature reviews. Cancer (2012) Vol. 12, Iss. 4, pp. 237-251
Open Access | Times Cited: 1465
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney, Paul D. Rennert, Gordon J. Freeman
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 8, pp. 561-584
Closed Access | Times Cited: 1200
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
New England Journal of Medicine (2016) Vol. 375, Iss. 18, pp. 1767-1778
Open Access | Times Cited: 1176
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci, Владимир Трифонов, Giulia Fabbri, et al.
Nature Genetics (2011) Vol. 43, Iss. 9, pp. 830-837
Open Access | Times Cited: 948
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 23, pp. 2698-2704
Open Access | Times Cited: 937
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes, Armando Santoro, Margaret A. Shipp, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 9, pp. 1283-1294
Open Access | Times Cited: 884
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H.C. Baumeister, Gordon J. Freeman, Glenn Dranoff, et al.
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 539-573
Closed Access | Times Cited: 835
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen, Bjoern Chapuy, Jing Ouyang, et al.
Clinical Cancer Research (2013) Vol. 19, Iss. 13, pp. 3462-3473
Open Access | Times Cited: 801
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr, Christina E. Sparbier, Yih-Chih Chan, et al.
Nature (2017) Vol. 549, Iss. 7670, pp. 101-105
Open Access | Times Cited: 781
Mechanisms Controlling PD-L1 Expression in Cancer
Jong‐Ho Cha, Li-Chuan Chan, Chia‐Wei Li, et al.
Molecular Cell (2019) Vol. 76, Iss. 3, pp. 359-370
Open Access | Times Cited: 746
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G.M. Roemer, Ranjana H. Advani, Azra H. Ligon, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 23, pp. 2690-2697
Open Access | Times Cited: 700
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
Kristin J. Lastwika, Willie Wilson, Qing Kay Li, et al.
Cancer Research (2015) Vol. 76, Iss. 2, pp. 227-238
Open Access | Times Cited: 688
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 14, pp. 1428-1439
Open Access | Times Cited: 688
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand, Margaret A. Shipp, Vincent Ribrag, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 31, pp. 3733-3739
Open Access | Times Cited: 644
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green, Scott J. Rodig, Przemysław Juszczyński, et al.
Clinical Cancer Research (2012) Vol. 18, Iss. 6, pp. 1611-1618
Open Access | Times Cited: 639
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda, et al.
Nature (2016) Vol. 534, Iss. 7607, pp. 402-406
Closed Access | Times Cited: 598
Page 1 - Next Page

Scroll to top